Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
P/S ratio for Nectar Lifesciences Limited (NECLIFE.NS)
P/S ratio as of 2023: 0.46
According to Nectar Lifesciences Limited's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.46. At the end of 2022 the company had a P/S ratio of 0.23.
P/S ratio history for Nectar Lifesciences Limited from 2005 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 0.46 |
| 2022 | 0.23 |
| 2021 | 0.32 |
| 2020 | 0.27 |
| 2019 | 0.09 |
| 2018 | 0.14 |
| 2017 | 0.33 |
| 2016 | 0.48 |
| 2015 | 0.51 |
| 2014 | 0.50 |
| 2013 | 0.33 |
| 2012 | 0.22 |
| 2011 | 0.42 |
| 2010 | 0.51 |
| 2009 | 0.65 |
| 2008 | 0.22 |
| 2007 | 0.39 |
| 2006 | 0.46 |
| 2005 | 1.26 |